NASDAQ:PGNY Progyny (PGNY) Stock Price, News & Analysis $27.93 +0.10 (+0.36%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$27.93 0.00 (0.00%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Progyny Stock (NASDAQ:PGNY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Progyny alerts:Sign Up Key Stats Today's Range$27.64▼$28.2450-Day Range$24.79▼$31.5352-Week Range$16.10▼$33.06Volume694,542 shsAverage Volume1.27 million shsMarket Capitalization$2.14 billionP/E Ratio30.36Dividend YieldN/APrice Target$34.36Consensus RatingModerate Buy Company Overview Progyny, Inc. (NASDAQ: PGNY) is a fertility and family-building benefits company that helps employers provide reproductive health services to their employees. Its platform is designed to support individuals and families navigating fertility treatment, preservation, adoption, surrogacy and related family-building needs. The company offers an integrated benefits solution that combines personalized care navigation with access to a network of fertility specialists and treatment providers. Progyny also provides pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments. Progyny primarily serves employer-sponsored benefit programs in the United States. The company was founded in 2016 and became a publicly traded company in 2019. Its leadership includes Peter Anevski, who serves as chief executive officer.AI Generated. May Contain Errors. Read More Progyny Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScorePGNY MarketRank™: Progyny scored higher than 87% of companies evaluated by MarketBeat, and ranked 50th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingProgyny has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 1 strong buy rating, 9 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialProgyny has a consensus price target of $34.36, representing about 23.0% upside from its current price of $27.93.Amount of Analyst CoverageProgyny has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Progyny's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth13.60% Earnings GrowthEarnings for Progyny are expected to grow by 13.60% in the coming year, from $1.25 to $1.42 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Progyny is 30.36, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.05.Price to Earnings Ratio vs. SectorThe P/E ratio of Progyny is 30.36, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.02.Price to Earnings Growth RatioProgyny has a PEG Ratio of 1.92. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioProgyny has a P/B Ratio of 4.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Progyny's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.36% of the float of Progyny has been sold short.Short Interest Ratio / Days to CoverProgyny has a short interest ratio ("days to cover") of 4.09.Change versus previous monthShort interest in Progyny has recently increased by 8.14%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProgyny does not currently pay a dividend.Dividend GrowthProgyny does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment0.80 News SentimentProgyny has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Progyny this week, compared to 4 articles on an average week.Search Interest4 people have searched for PGNY on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added Progyny to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Progyny insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $423,178.00 in company stock.Percentage Held by Insiders9.90% of the stock of Progyny is held by insiders.Percentage Held by Institutions94.93% of the stock of Progyny is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Progyny's insider trading history. Receive PGNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PGNY Stock News HeadlinesAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Progyny (PGNY) and Merck & Company (MRK)October 9 at 2:03 PM | theglobeandmail.comWhy are Progyny (PGNY) shares soaring todayOctober 7 at 10:38 PM | msn.comNo. 1 stock to cash in on the death of iPhoneAnalyst Josh Baylin, who warned Congress about smartphones years before the iPhone launched, says the world's richest man may be building an iPhone rival he calls Starphone. Baylin points to FCC rulings, two trademarks filed the same day, multibillion-dollar spectrum deals, chip partnerships, and a string of posts from Elon Musk as evidence pointing to one conclusion. See the full research and the stock Baylin is watching now.October 10 at 1:00 AM | Stansberry Research (Ad)PGNY or CRL: Which Is the Better Value Stock Right Now?October 7 at 12:36 PM | finance.yahoo.comProgyny, Inc. Selling Season Pacing to Record Level, Revealing Critical Insights on Latest Market DynamicsOctober 7 at 8:28 AM | globenewswire.comProgyny (NASDAQ:PGNY) Stock Picked Up by Analysts at Wells Fargo & CompanyOctober 2, 2026 | americanbankingnews.comProgyny (NASDAQ:PGNY) EVP Sells 3,903 Shares of StockSeptember 29, 2026 | insidertrades.comInsider Selling: Progyny (NASDAQ:PGNY) Director Sells $321,310.00 in StockSeptember 15, 2026 | insidertrades.comSee More Headlines PGNY Stock Analysis - Frequently Asked Questions How have PGNY shares performed this year? Progyny's stock was trading at $25.68 at the start of the year. Since then, PGNY stock has increased by 8.8% and is now trading at $27.93. How were Progyny's earnings last quarter? Progyny, Inc. (NASDAQ:PGNY) released its earnings results on Thursday, August, 6th. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.22. The company's revenue was up 5.3% compared to the same quarter last year. Read the conference call transcript. Is Progyny doing a stock buyback? Progyny's Board of Directors authorized a stock repurchase program on Tuesday, May 26th 2026, which authorizes the company to repurchase $200,000,000 in shares, according to EventVestor. This means that the company could buy up to 10.3% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's leadership believes its stock is undervalued. When did Progyny IPO? Progyny (PGNY) raised $150 million in an initial public offering on Friday, October 25th 2019. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers. Who are Progyny's major shareholders? Progyny's top institutional investors include Central Pacific Bank Trust Division (0.01%) and Toth Financial Advisory Corp. Insiders that own company stock include Peter Anevski, Michael E Sturmer, David J Schlanger, Allison Swartz, Mark S Livingston, Melissa B Cummings, Geoffrey Clapp, Cheryl Scott and Kevin K Gordon. View institutional ownership trends. How do I buy shares of Progyny? Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Progyny own? Based on aggregate information from My MarketBeat watchlists, some other companies that Progyny investors own include Humana (HUM), American Water Works (AWK), NVIDIA (NVDA), Rambus (RMBS), Voyager Therapeutics (VYGR), Saia (SAIA) and Waste Connections (WCN). Company Calendar Last Earnings8/06/2026Today10/10/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 3 days ago, PGNY's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolNASDAQ:PGNY CIK1551306 Webwww.progyny.com Phone212-888-3124FaxN/AEmployees856Year Founded2008Price Target and Rating Average Price Target for Progyny$34.36 High Price Target$40.00 Low Price Target$30.00 Potential Upside/Downside+23.0%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)$0.92 Trailing P/E Ratio30.36 Forward P/E Ratio22.34 P/E Growth1.92Net Income$58.52 million Net Margins6.00% Pretax Margin9.14% Return on Equity15.98% Return on Assets10.65% Debt Debt-to-Equity RatioN/A Current Ratio2.14 Quick Ratio2.14 Sales & Book Value Annual Sales$1.29 billion Price / Sales1.66 Cash Flow$0.74 per share Price / Cash Flow37.80 Book Value$5.99 per share Price / Book4.66Miscellaneous Outstanding Shares76,730,000Free Float69,131,000Market Cap$2.14 billion OptionableOptionable Beta1.02 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:PGNY) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredA major gold reset could be closer than people thinkFor 50 years, Washington has held 8,133 tonnes of gold on its books at a fraction of today's market price. One...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Progyny, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Progyny With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
